Arthur Allen, Gregory Piazza, Margaret Fang/LinkedIn
Sep 12, 2025, 15:44
Long-Term Apixaban Use for Provoked VTE: Focus on HI-PRO Trial by Arthur Allen, Margaret Fang and Gregory Piazza
Anticoagulation Forum shared on LinkedIn:
”Join us for our free October webinar: Emerging Evidence: Long-term oral anticoagulation following provoked VTE? A focus on the HI-PRO Trial
Tuesday, October 7, 2025 | 12:00 PM ET
Join us as expert faculty review findings from the recent HI-PRO Trial on the use of apixaban for extended treatment of provoked venous thromboembolism (VTE).
What you’ll learn:
- Key insights from trial design and results
- Clinical implications for real-world practice
- Patient selection considerations for extended therapy
Faculty:
Arthur Allen, PharmD, CACP – Salt Lake City Va Health Care System
Margaret Fang, MD, MPH – University of California, San Francisco
Gregory Piazza, MD, MS – Brigham and Women’s Hospital”
Register here.
Stay informed on all webinars and seminars in the field of thrombosis with Hemostasis Today.
-
Mar 20, 2026, 16:42Charlie Zhou: Exploring the Potential of Immune Reset Therapies in Autoimmune Cytopenias
-
Mar 20, 2026, 16:40Kate G.: Moving Beyond Being ‘Just a Carrier’
-
Mar 20, 2026, 16:31Jerome Winegarden: ASH Continues to Show Exceptional Leadership by Advocating for Patients With Blood Diseases
-
Mar 20, 2026, 16:28Breanna Beers: A Remarkable Case of ‘Generation Skipping’ Marfan Syndrome
-
Mar 20, 2026, 16:26Results from The HUNT Study on The Role of Plasma miR-145-5p Levels in Cancer-Associated VTE – JTH
-
Mar 20, 2026, 16:23Eva Soler Espejo։ Atherogenic Index of Plasma and Residual Risk in Atrial Fibrillation
-
Mar 20, 2026, 16:22Welcoming Samer Al Hadidi to the Blood Cancers Team – UT Southwestern Simmons Cancer Center
-
Mar 20, 2026, 16:21Maxime Dely: The Lifesaving Power of Plasma Donations
-
Mar 20, 2026, 16:20Yves Bikorimana: Hemolysis – Why It Ruins Laboratory Results